CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Sep. 26, 2020	Sep. 28, 2019
Cash Flows from Operating Activities:
Net income	$ 58,628	$ 29,007
Non-cash items:
Depreciation and amortization	41,603	54,469
Impairment of assets	1,028	48,721
Share-based compensation expense	12,119	9,730
Deferred tax benefit	(3,031)	(7,290)
Provision for losses on accounts receivable and inventory	1,057	(1,857)
Gains on divestitures and sale of assets	(31,498)	(8,083)
Other non-cash operating activities	362	140
Change in operating assets and liabilities:
Change in accounts receivable	22,391	7,806
Change in inventories	(38,189)	(59,439)
Change in prepaid income taxes	(635)	(1,588)
Change in other assets and other liabilities	1,902	(10,616)
Change in accounts payable and accrued expenses	(24,770)	(28,471)
Net cash provided by operating activities	40,967	32,529
Cash Flows from Investing Activities:
Capital expenditures	(16,035)	(17,722)
Acquisition	(16,606)	0
Proceeds from divestitures	44,978	9,808
Proceeds from sale of property, plant and equipment	902	15,739
Net cash provided by investing activities	13,239	7,825
Cash Flows from Financing Activities:
Net increase in short-term loans	90,000	25,000
Repayment of term loan borrowings	(8,750)	(4,375)
Share repurchases	0	(125,000)
Proceeds from employee stock purchase plan	2,144	1,830
Proceeds from exercise of stock options	1,259	6,046
Other	(20)	72
Net cash provided by (used in) financing activities	84,633	(96,427)
Effect of exchange rates on cash and cash equivalents	3,019	(1,248)
Net Change in Cash and Cash Equivalents	141,858	(57,321)
Cash and Cash Equivalents at Beginning of Period	137,311	169,351
Cash and Cash Equivalents at End of Period	279,169	112,030
Supplemental Disclosures of Cash Flow Information:
Interest paid	4,637	6,260
Income taxes paid	4,099	8,535
Transfers from inventory to fixed assets for placement of Haemonetics equipment	$ 4,203	$ 5,780